The Health Sciences Authority (HSA) is suspending the sales of sibutramine products in Singapore with effect from today, after consulting its Pharmacovigilance Advisory Committee (PVAC) and a panel of external experts in metabolic diseases and cardiology.Sibutramine is licensed for use in Singapore since 2001 as an adjunctive therapy to diet and exercise for obesity and for overweight patients with obesity-related risk factors such as Type 2 diabetes or disorders in lipid metabolism.
It is marketed under four different brands in Singapore – Reductil®, Ectiva®, Reduxade® (all by Abbott) and Slenfig® (Apotheca Marketing). Full story
